SCHEMBL4044931

SCHEMBL4044931

COc1ccc(CC(NC(=O)c2ccc(C(C)(C)C)cc2)C(=O)N2CCC3C2C(=O)CN3C(=O)Cc2cccnc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 4/20 0.54
GPR132 Q9UNW8 2/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNA7 P36544 1/20 0.41
CHRNA4 P43681 1/20 0.41
CTSS P25774 1/20 0.40
USP30 Q70CQ3 1/20 0.40
GAA P10253 1/20 0.40
ACE P12821 2/20 0.39
F2 P00734 2/20 0.39
CXCR3 P49682 1/20 0.39
MAPT P10636 2/20 0.39
PLG P00747 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
SLC18A3 Q16572 1/20 0.38
PTAFR P25105 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043376 0.92 CTSK (0.56) CTSKGPR132CHRNB2CHRNA4CTSS
SCHEMBL4046339 0.92 CTSK (0.55) CTSKGPR132CHRNB2CHRNA7CHRNA4
SCHEMBL4046945 0.89 CTSK (0.55) CTSKCHRNB2CHRNA7CHRNA4CTSS
SCHEMBL4039388 0.89 CTSK (0.45) CTSKGPR132CHRNB2CHRNA7CHRNA4
SCHEMBL4041333 0.89 CTSK (0.69) CTSKCTSSGAAACEMAPT
SCHEMBL4046323 0.88 CTSK (0.54) CTSKGPR132CTSSGAAACE
SCHEMBL4037811 0.88 CTSK (0.57) CTSKGPR132CTSSGAAACE
SCHEMBL4049108 0.88 CTSK (0.57) CTSKGPR132CTSSGAAACE
SCHEMBL4044253 0.87 CTSK (0.48) CTSKGPR132CHRNB2CHRNA7CHRNA4
SCHEMBL4044071 0.86 CTSK (0.54) CTSKCHRNA7CTSSGAAACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP claimed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US disclosed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP disclosed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS CTSK 2/4885GPR132 844/4885CHRNB2 3423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.